NCT06702293 Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients
| NCT ID | NCT06702293 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National University Hospital, Singapore |
| Condition | Eczema |
| Study Type | INTERVENTIONAL |
| Enrollment | 690 participants |
| Start Date | 2026-02-23 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 690 participants in total. It began in 2026-02-23 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Skin diseases, despite low mortality, significantly impair quality of life. This randomised controlled trial evaluates the efficacy of a digital toolkit comprising psychotherapeutic strategies in reducing QoL burden in patients with chronic inflammatory skin conditions. This toolkit is hosted on a mobile application and will be used by study participants randomised to the intervention arm over the 32 week study period.
Eligibility Criteria
Inclusion Criteria: * Patients with psoriasis, eczema or chronic urticaria diagnosed by a dermatologist * Aged 16 or older * Peak pruritus intensity of 4 or more on a 11-point numerical rating scale (0-10, with 10 representing worst itch) * Able to engage with a mobile application in the English language Exclusion Criteria: * Patients with active psychiatric symptoms (e.g. active suicidal ideation, psychosis, delusions) * Patients with unstable psychiatric condition, characterized by o Hospital inpatient admission for a psychiatric condition or initiation of a psychotropic medication in the prior 3 months * Patients with unstable dermatological condition, characterized by * Recent flare of the skin condition within the last 2 weeks, including diagnosis of a flare by a doctor, use of systemic steroids, oral antibiotics, wet wrap rescue therapy, oral antivirals, or increase in frequency of phototherapy or dose of systemic medications for the dermatological condition within the last 2 weeks OR * Any of the following within 3 months * inpatient admission for a dermatological condition * Initiation of phototherapy * Initiation of systemic therapy (conventional immunosuppressive agent, biologics, JAK inhibitors) within the last 3 months.
Contact & Investigator
Ellie Choi, MBBS
PRINCIPAL INVESTIGATOR
National University Hospital, Singapore
Frequently Asked Questions
Who can join the NCT06702293 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Eczema. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06702293 currently recruiting?
Yes, NCT06702293 is actively recruiting participants. Contact the research team at dermatology@nuhs.edu.sg for enrollment information.
Where is the NCT06702293 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT06702293 clinical trial?
NCT06702293 is sponsored by National University Hospital, Singapore. The principal investigator is Ellie Choi, MBBS at National University Hospital, Singapore. The trial plans to enroll 690 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.